Compare Sanofi SA (SNY) vs SpaceX (SPCX) Price & Performance

Sanofi SATrade

SpaceXTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs SpaceX — how do they compare? Sanofi SA trades at $40.14 (market cap $95.18B), while SpaceX trades at $161.53 (market cap $2.18T). The key difference: SpaceX is far larger — about 22.9× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while SpaceX pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and SpaceX for 41 Days on average.

	SNY	SPCX
Market Cap	$95.18B	$2.18T
Volume	2,995,646	68,508,567
Sector	Health	Industrials
52-Week High	$52.34	$202.09
52-Week Low	$39.51	$108.27
Typical Hold Time	94 Days	41 Days
Enterprise Value	$114.48B	$2.12T
Dividend Yield	6.01%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.

The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.

SpaceX

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNY

35% Buy65% Sell

Avg holding period · 94 Days

SPCX

54% Buy46% Sell

Avg holding period · 41 Days

Top news

Latest headlines on both assets

SNY

Biopharma leaders showcase AI and cloud tech to speed drug development at Veeva SummitPRNewsWire · 1 day agoBullish Novavax jumps 22% as Sanofi advances Nuvaxovid for fall vaccinations, outpacing Moderna and BioNTech.24/7 Wall Street · 4 days agoBullish View details →

SPCX

AST SpaceMobile shares drop 6% as SpaceX secures low-band spectrum, tightening competition for satellite phone links.24/7 Wall Street · 9 hours agoBearish SpaceX's Starlink expands mobile service, pressuring AT&T, Verizon, and T-Mobile shares.Proactive Investors · 10 hours agoBearish SpaceX rises 4% after buying nationwide low-band spectrum, pressuring Verizon and AT&T stocks down 7%.24/7 Wall Street · 11 hours agoNeutral View details →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.